Supplementary Figures from Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma
Authors: Peng Hao , Dong Di , Fang Meng-Jie , Li Lu , Tang Ling-Long , Chen Lei , Li Wen-Fei , Mao Yan-Ping , Fan Wei , Liu Li-Zhi , Tian Li , Lin Ai-Hua , Sun Ying , Tian Jie , Ma Jun 
Published: April 2023

<p>Figure S1. Flow chart of patient inclusion. NPC, nasopharyngeal carcinoma; PET/CT, positron emission tomography with computed tomography; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; IMRT, intensity-modulated radiotherapy. Figure S2. The manual segmentation of (A) a patient with disease progression and (B) a patient without disease progression. Red region, the segmented tumors; green region, the segmented lymph nodes. Figure S3. DCNN architectures used in the study. (A) DCNN for CT image in training step; (B) DCNN for CT image in feature extraction step; (C) DCNN for PET image in training step; (D) DCNN for PET image in feature extraction step. Figure S4. Time-dependent ROC curves of radiomics nomogram in the training (A) and test (B) sets. ROC, receiver operating characteristic; AUC, area under the curve. Figure S5. Radiomics nomogram score for each patients in the training (A) and test (B) sets. Figure S6. Kaplan-Meier survival curves of disease-free survival between high-risk and low-risk groups stratified by age, gender, overall stage, and pre-DNA. Figure S7. Kaplan-Meier survival curves of overall survival between high-risk and low-risk groups stratified by age, gender, overall stage and pre-DNA. Figure S8. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for the whole 707 patients. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival. Figure S9. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for the 521 patients with low risk. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy. DFS, disease-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival. Figure S10. An example of the feature maps generated from the DCNNs. Figure S11. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for nomogram A-defined low-risk group. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; S, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival. Figure S12. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for nomogram A-defined high-risk group. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; S, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival. Figure S13. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for nomogram B-defined low-risk group. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; S, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival. Figure S14. Kaplan-Meier survival curves of DFS (A), OS (B), DMFS (C) and LRRFS (D) between IC+CCRT and CCRT alone for nomogram B-defined high-risk group. IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; S, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival.</p>